Tasche M J, De Jongste J C
Erasmus Universiteit, Instituut Huisartsgeneeskunde, Rotterdam.
Ned Tijdschr Geneeskd. 1998 Apr 11;142(15):828-9.
Recently a randomised placebo controlled trial in a general practice setting showed that inhaler therapy with a spacer device in 218 1-4 year old children with moderate asthma is feasible, but that treatment with cromoglycate was no more effective than placebo. The lack of benefit from the treatment with cromoglycate may have resulted from several points discussed and refuted in this commentary. Major points are the degree of asthma of the children and uncertainty about the amount of medication that reached the lungs. The results of the trial support the intentions of national and international guidelines to withdraw the recommendation of cromoglycate as the first choice in prophylactic asthma treatment.
最近在一项全科医疗环境下的随机安慰剂对照试验表明，对218名1至4岁的中度哮喘儿童使用带储雾罐的吸入器疗法是可行的，但色甘酸盐治疗并不比安慰剂更有效。色甘酸盐治疗缺乏益处可能源于本评论中讨论并反驳的几个要点。主要要点包括儿童哮喘的程度以及到达肺部的药物量的不确定性。该试验结果支持了国家和国际指南取消将色甘酸盐作为预防性哮喘治疗首选推荐的意图。
